Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer.

IF 8.4 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2026-05-15 DOI:10.1038/s41523-026-00968-3

Caterina Marchiò, Federico Rojo, Ellen R Copson, Fernando Schmitt, Beatriz Bellosillo, Carlo Fremd

引用次数: 0

Abstract

PIK3CA mutations are common in HR+/HER2- metastatic breast cancer and guide the use of PI3K-targeted therapies. This expert consensus provides recommendations on timing, methods, and interpretation of PIK3CA testing, emphasizing early assessment at metastatic diagnosis, preferred use of NGS panels, and standardized pre-analytical workflows. Reflex and dual-sample strategies can reduce delays and failures. Implementation requires coordinated logistics, education across the diagnostic chain, and equitable access to ensure timely, personalized treatment.

查看原文本刊更多论文

专家建议在HR+/HER2-局部晚期和转移性乳腺癌中检测PIK3CA。

PIK3CA突变在HR+/HER2-转移性乳腺癌中很常见，并指导了pi3k靶向治疗的使用。这一专家共识提供了关于PIK3CA检测的时间、方法和解释的建议，强调转移诊断的早期评估，优先使用NGS小组，以及标准化的分析前工作流程。反射和双样本策略可以减少延迟和失败。实施需要协调后勤、整个诊断链的教育和公平获取，以确保及时、个性化的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.